Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Mednax, Inc. (MD)

MD, FPI

PR Newswire

NEW YORK, July 11, 2018 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mednax, Inc. ("Mednax" or the "Company") (NYSE: MD). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/md.

Bronstein, Gewirtz & Grossman, LLC

The investigation concerns whether Mednax and certain of its officers and/or directors have violated federal securities laws.

On April 20, 2017, Mednax announced negative financial results for the first quarter of 2017, including missed earnings.  Mednax cited negative trends including "payor mix" degradation, lower volume of newborn infant patients, and wage inflation, with half of the financial impact related to business in North Carolina and Texas.  On this news, Mednax's stock price fell $5.39 per share, or 8.1%, to close at $61.30 per share on April 20, 2017.  Then, on July 28, 2017, during its second quarter earnings call with investors and analysts, Mednax announced that the Company had failed to complete any acquisitions of anesthesiologist practices during the quarter and that any future anesthesiologist acquisitions were unlikely, citing the "challenging" payor mix combined with "continued . . . growth in compensation expense for nurse anesthetists."  On this news, Mednax's stock price fell $8.76 per share, or 15.5%, to close at $47.73 per share on July 28, 2017.

If you are aware of any facts relating to this investigation, or purchased Mednax shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/md  You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-mednax-inc-md-300679597.html

SOURCE Bronstein, Gewirtz & Grossman, LLC



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today